|
AAZ-A-154
AAZ-A-154 is a novel isotryptamine derivative which acts as a 5-HT2A receptor, 5-HT2A receptor agonist discovered and synthesized by the lab of Professor David E. Olson at University of California, Davis, UCDavis. Animal studies suggest that it produces antidepressant effects without the psychedelic action typical of drugs from this class. In tests, AAZ-A-154 had antidepressant effects in mice without causing the head-twitch response linked to hallucinogenic effects. Due to the rapidly-induced and enduring neuroplasticity, AAZ-A-154 is a member of the class of compounds known as non-hallucinogenic psychoplastogens. This compound, as well as related compounds, are licensed by Delix Therapeutics and are being developed as potential medicines for Mental disorder, neuropsychiatric disorders. See also * α,N,N-Trimethyltryptamine * 5-MeO-DMT * 6-Fluoro-DET * AL-34662 * IHCH-7113 * (R)-69 * Neuroplasticity * Psychoplastogen * Delix Therapeutics * David E. Olson References Desi ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Psychoplastogen
Psychoplastogens are a group of small molecule drugs that produce rapid and sustained effects on neuronal structure and function, intended to manifest therapeutic benefit after a single administration. Several existing psychoplastogens have been identified and their therapeutic effects demonstrated; several are presently at various stages of development as medications including Ketamine, Rapastinel, MDMA, Scopolamine, and the serotonergic psychedelics, including LSD, psilocin – the active metabolite of psilocybin, DMT, and 5-MeO-DMT. Compounds of this sort are being explored as therapeutics for a variety of brain disorders including depression, addiction, and PTSD. The ability to rapidly promote neuronal changes via mechanisms of neuroplasticity was recently discovered as the common therapeutic activity and mechanism of action. Etymology and nomenclature The term psychoplastogen comes from the Greek roots - (mind), - (molded), and - (producing) and covers a variety of chem ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Psychoplastogen
Psychoplastogens are a group of small molecule drugs that produce rapid and sustained effects on neuronal structure and function, intended to manifest therapeutic benefit after a single administration. Several existing psychoplastogens have been identified and their therapeutic effects demonstrated; several are presently at various stages of development as medications including Ketamine, Rapastinel, MDMA, Scopolamine, and the serotonergic psychedelics, including LSD, psilocin – the active metabolite of psilocybin, DMT, and 5-MeO-DMT. Compounds of this sort are being explored as therapeutics for a variety of brain disorders including depression, addiction, and PTSD. The ability to rapidly promote neuronal changes via mechanisms of neuroplasticity was recently discovered as the common therapeutic activity and mechanism of action. Etymology and nomenclature The term psychoplastogen comes from the Greek roots - (mind), - (molded), and - (producing) and covers a variety of chem ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Delix Therapeutics
Delix Therapeutics is an American biotech company based in Boston, Massachusetts. The company develops novel neuroplasticity-promoting therapeutics for central nervous system (CNS) diseases such as depression and post-traumatic stress disorder (PTSD). It was co-founded in 2019 by David E. Olson and Nick Haft. Company History The company was founded to develop novel psychoplastogens to better treat mental health disorders at scale. David E. Olson founded the company following his discovery that psychedelics are highly potent neuroplasticity-promoting compounds. In September 2021, Delix secured a Series A financing round to continue their work focused on psychoplastogens and neuroplasticity therapeutics. Also in Fall of 2021, Delix joined the National Institute on Drug Abuse industry partnering program to screen psychoplastogens in models of substance use disorder. In 2021, the company expanded the leadership team, adding a new CEO, CSO, and CMO Product Candidates To date, ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
5-HT2A Receptor
The 5-HT2A receptor is a subtype of the 5-HT2 receptor that belongs to the serotonin receptor family and is a G protein-coupled receptor (GPCR). The 5-HT2A receptor is a cell surface receptor, but has several intracellular locations. 5-HT is short for 5-hydroxy-tryptamine or serotonin. This is the main excitatory receptor subtype among the GPCRs for serotonin, although 5-HT2A may also have an inhibitory effect on certain areas such as the visual cortex and the orbitofrontal cortex. This receptor was first noted for its importance as a target of serotonergic psychedelic drugs such as LSD and psilocybin mushrooms. Later it came back to prominence because it was also found to be mediating, at least partly, the action of many antipsychotic drugs, especially the atypical ones. Downregulation of post-synaptic 5-HT2A receptor is an adaptive process provoked by chronic administration of selective serotonin reuptake inhibitors (SSRIs) and atypical antipsychotics. Suicidal and otherwis ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
(R)-69
(''R'')-69 (3IQ) is a tetrahydropyridine derivative which acts as a 5-HT2A receptor agonist, with 4.6x selectivity over 5-HT2B and 49x selectivity over 5-HT2C. It has a 5-HT2A Ki of 680nM and an EC50 of 41nM. (''R'')-69 is a biased agonist selective for activation of the Gq coupled signalling pathway, with much weaker activation of the β-arrestin 2 coupled pathway. In animal studies it produces antidepressant-like activity but without producing the head-twitch response associated with psychedelic effects. See also * AAZ-A-154 * RU-24969 * SN-22 SN-22 is a chemical compound which acts as a moderately selective agonist at the 5-HT2 family of serotonin receptors, with a Ki of 19nM at 5HT2 subtypes vs 514 nM at 5-HT1A receptors. Many related derivatives are known, most of which are ligand ... References Designer drugs Pyrrolopyridines Tetrahydropyridines {{nervous-system-drug-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
IHCH-7113
IHCH-7113 is a drug which acts as an agonist at the 5-HT2A receptor, 5-HT2A serotonin Receptor (biochemistry), receptor. It was derived by structural simplification of the 5-HT2A antagonist atypical antipsychotic drug lumateperone along with several related compounds such as IHCH-7079 and IHCH-7086, which were found to be nonhallucinogenic biased 5-HT2A agonists that were active in antidepressant assays but did not produce psychedelic-like responding in mice. IHCH-7113 however produced a head-twitch response comparable to that of 2,5-Dimethoxy-4-iodoamphetamine, DOI or LSD, which was blocked by the 5-HT2A antagonist MDL100907. yrrolo [1,2,3-de]quinoxalin-8-(7H ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AL-34662
AL-34662 is an indazole derivative drug that is being developed for the treatment of glaucoma. It acts as a selective 5-HT2A receptor agonist, the same target as that of psychedelic drugs like psilocin, but unlike these drugs, AL-34662 was designed specifically as a peripherally selective drug, which does not cross the blood–brain barrier. This means that AL-34662 can exploit a useful side effect of the hallucinogenic 5-HT2A agonists, namely reduction in intra-ocular pressure and hence relief from the symptoms of glaucoma, but without causing the hallucinogenic effects that make centrally active 5-HT2A agonists unsuitable for clinical use. In animal studies, AL-34662 has been shown to be potent and effective in the treatment of symptoms of glaucoma, with minimal side effects. Peripherally acting 5-HT2A agonists have been a rich field of research in recent years, with potential glaucoma treatments being the main proposed application for 5-HT2A agonists at present, as centrally ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
6-Fluoro-DET
6-Fluoro-DET (6F-DET, 6-fluoro-''N,N''-diethyltryptamine) is a substituted tryptamine derivative related to drugs such as DET and 5-fluoro-DET. It acts as a partial agonist at the 5-HT2A receptor, but while it produces similar physiological effects to psychedelic drugs, it does not appear to produce psychedelic effects itself even at high doses. For this reason it saw some use as an active placebo in early clinical trials of psychedelic drugs but was regarded as having little use otherwise, though more recent research into compounds such as AL-34662 and AAZ-A-154 has shown that these kind of non-psychedelic 5-HT2A agonists can have various useful applications. See also * 5F-DMT * 5F-DET * 5F-MET * 5F-EPT 5-Fluoro-EPT (5F-EPT, 5-fluoro-''N''-ethyl-''N''-propyltryptamine) is a psychedelic tryptamine derivative related to drugs such as EPT and 5-MeO-EPT. It acts as a potent full agonist at the 5-HT2A receptor with an EC50 of 5.54 nM and an effi ... * 6F-AMT * 6F-DMT ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
α,N,N-Trimethyltryptamine
α,''N'',''N''-Trimethyltryptamine (α,''N'',''N''-TMT, α-TMT, ATMT) is a psychoactive drug of the tryptamine chemical class which acts as a psychedelic hallucinogen. It is similar in structure to the other psychedelics of the tryptamine class such as dimethyltryptamine (DMT) and α-methyltryptamine (α-MT). α-TMT has been tested in animals in comparison with α-MT and was found to produce similar effects, but with only around half the potency. See also * AAZ-A-154 AAZ-A-154 is a novel isotryptamine derivative which acts as a 5-HT2A receptor, 5-HT2A receptor agonist discovered and synthesized by the lab of Professor David E. Olson at University of California, Davis, UCDavis. Animal studies suggest that it ... * Ciclindole * MPMI References Psychedelic tryptamines Dimethylamino compounds {{hallucinogen-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Neuroplasticity
Neuroplasticity, also known as neural plasticity, or brain plasticity, is the ability of Neural circuit, neural networks in the brain to change through growth and reorganization. It is when the brain is rewired to function in some way that differs from how it previously functioned. These changes range from individual neuron pathways making new connections, to systematic adjustments like cortical remapping. Examples of neuroplasticity include circuit and network changes that result from learning a new ability, environmental influences, practice, and psychological stress. Neuroplasticity was once thought by neuroscientists to manifest only during childhood, but research in the latter half of the 20th century showed that many aspects of the brain can be altered (or are "plastic") even through adulthood. However, the developing brain exhibits a higher degree of plasticity than the adult brain. Activity-dependent plasticity can have significant implications for healthy development, le ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Mental Disorder
A mental disorder, also referred to as a mental illness or psychiatric disorder, is a behavioral or mental pattern that causes significant distress or impairment of personal functioning. Such features may be persistent, relapsing and remitting, or occur as single episodes. Many disorders have been described, with signs and symptoms that vary widely between specific disorders. Such disorders may be diagnosed by a mental health professional, usually a clinical psychologist or psychiatrist. The causes of mental disorders are often unclear. Theories may incorporate findings from a range of fields. Mental disorders are usually defined by a combination of how a person behaves, feels, perceives, or thinks. This may be associated with particular regions or functions of the brain, often in a social context. A mental disorder is one aspect of mental health. Cultural and religious beliefs, as well as social norms, should be taken into account when making a diagnosis. Services are b ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
David E
David (; , "beloved one") (traditional spelling), , ''Dāwūd''; grc-koi, Δαυΐδ, Dauíd; la, Davidus, David; gez , ዳዊት, ''Dawit''; xcl, Դաւիթ, ''Dawitʿ''; cu, Давíдъ, ''Davidŭ''; possibly meaning "beloved one". was, according to the Hebrew Bible, the Kings of Israel and Judah, third king of the Kingdom of Israel (united monarchy), United Kingdom of Israel. In the Books of Samuel, he is described as a young shepherd and Lyre, harpist who gains fame by slaying Goliath, a champion of the Philistines, in southern Canaan. David becomes a favourite of Saul, the first king of Israel; he also forges David and Jonathan, a notably close friendship with Jonathan (1 Samuel), Jonathan, a son of Saul. However, under the paranoia that David is seeking to usurp the throne, Saul attempts to kill David, forcing the latter to go into hiding and effectively operate as a fugitive for several years. After Saul and Jonathan are both killed in battle against the Philistin ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
